Passage Bio logo
Passage Bio
PASG | NASDAQ
Chart Builder DCF Calculator
$4.13
-$0.12 (-2.82%)
At close: Nov 16, 2026, 4:00 PM ET
$4.13
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

Passage Bio Company Profile

Company profile explained

Company Profile

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

Key Executives

Name Position
William Chou President, Chief Executive Officer & Director
Kathleen Borthwick Senior Vice President, Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Oct 09, 2026 EFFECT Filing
Oct 09, 2026 424B3 Filing
Oct 08, 2026 S-4/A [Amend] Filing
Oct 05, 2026 S-4/A [Amend] Filing
Sep 21, 2026 S-4/A [Amend] Filing
Sep 03, 2026 S-4/A [Amend] Filing
Sep 03, 2026 425 Filing
Sep 03, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 10, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Passage Bio
Passage Bio logo
Country United States
IPO Date Feb 28, 2020
Industry Biotechnology
Sector Healthcare
Employees 24
CEO William Chou

Contact Details

One Commerce Square Philadelphia, Pennsylvania 19103 United States

Stock Details

Ticker Symbol PASG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001787297
CUSIP Number 702712209
ISIN Number US7027122099
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.